Correction
Published on 12 Jan 2024
Corrigendum: Approach for delabeling beta-lactam allergy in children
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1361973
- 1,030 views
Type at least 3 characters
59 articles
Articles
Review
Published on 14 Dec 2023
Potential and limitations of epitope mapping and molecular targeting in Hymenoptera venom allergy
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1327391
- 3,068 views
- 1 citation
Review
Published on 15 Nov 2023
Approach for delabeling beta-lactam allergy in children
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1298335
- 3,810 views
- 5 citations
Editorial
Published on 19 Sep 2023
Editorial: Antibiotic allergy de-labelling and management
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1278690
- 1,289 views
- 1 citation
Brief Research Report
Published on 31 Jul 2023
Use of a beta-lactam graded challenge process for inpatients with self-reported penicillin allergies at an academic medical center
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1161683
- 3,683 views
- 1 citation
Case Report
Published on 27 Jul 2023
Severe exercise-induced anaphylaxis in a hot and humid area successfully treated with omalizumab: a case report
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1228495
- 2,374 views
- 3 citations
Editorial
Published on 13 Jul 2023
Editorial: Assessment and management of adverse drug reactions in oncology
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1223078
- 1,729 views
Original Research
Published on 04 Jul 2023
Multicolor flow cytometry-based immunophenotyping for preclinical characterization of nanotechnology-based formulations: an insight into structure activity relationship and nanoparticle biocompatibility profiles
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1126012
- 2,590 views
- 2 citations
Editorial
Published on 24 May 2023
Editorial: Immune-related adverse Events (irAEs) of biopharmaceuticals
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1214914
- 1,456 views
Editorial
Published on 11 May 2023
Editorial: Diagnosis and management of allergy to chemotherapy and biologics
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1205345
- 2,355 views
- 2 citations
Case Report
Published on 09 May 2023
Case report: Insulin desensitization as the only option for managing insulin allergy in a Sudanese patient
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1089966
- 2,378 views
- 1 citation
Brief Research Report
Published on 03 May 2023
Anaphylaxis induced by mRNA COVID-19 vaccines: follow-up and booster dose after previous desensitization
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1056619
- 2,088 views
- 1 citation
Brief Research Report
Published on 30 Mar 2023
A potential cost savings analysis of a penicillin de-labeling program
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1101321
- 2,170 views
- 4 citations
Mini Review
Published on 16 Mar 2023
Delabelling multiple antibiotic allergy: Practical issues
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1156137
- 4,694 views
- 3 citations
Mini Review
Published on 02 Mar 2023
Mucocutaneous adverse events to immune checkpoint inhibitors
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2023.1147513
- 4,822 views
- 4 citations
Original Research
Published on 06 Jan 2023
Cofactors of drug hypersensitivity—A monocenter retrospective analysis
in Drug, Venom & Anaphylaxis
Frontiers in Allergy
doi 10.3389/falgy.2022.1097977
- 2,025 views
- 1 citation